In particular, the administration of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARB) could be of particular benefit in DM1 due to anti-fibrotic properties [7] and they are recommended when LVEF is lower than 50%. This evidence concerns the gene ACE and myotonic dystrophy type 1.